A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

NCT02148133 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytopaenia

Interventions

DRUG: Eltrombopag 12.5 mg
DRUG: Eltrombopag 25 mg

Sponsor

Novartis Pharmaceuticals